Program
Sirolimus
Also written as “sirolimus”, “Rapamycin” and “Sirolimus for Injection (Albumin-bound)”.
Its studies are mostly in Renal Insufficiency · Kidney Failure, Chronic · Breast Neoplasms · Tuberous Sclerosis · Uveitis, led by 18 companies.
Drug pageSirolimus: every studyMany companies study it; this page follows only the 65 they lead. All 505 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Pfizerits history only | 260 open or running | phase 4since Sep 4, 2002 | May 17, 2002 | none ahead |
| CSPC Pharmaceutical Group | 85 open or running | phase 3since Apr 8, 2025 | Oct 25, 2021 | Oct 2027phase 1 · NCT06941142 |
| Santen Pharmaceuticalits history only | 70 open or running | phase 3since May 19, 2011 | Nov 15, 2006 | none ahead |
| Astellas Pharmaits history only | 31 open or running | phase 4since May 31, 2011 | May 31, 2011 | Oct 31, 2027phase 2 · NCT07052929 |
| Umoja Biopharmaits history only | 33 open or running | phase 2since Jul 24, 2026 | Jul 25, 2024 | Mar 2029phase 1 · NCT06528301 |
| AgelessRxits history only | 21 open or running | phase 3since Dec 18, 2024 | Jul 13, 2020 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 20 open or running | phase 1since Nov 18, 2014 | Nov 18, 2014 | none ahead |
| Hoffmann-La Rocheits history only | 20 open or running | phase 4since Jul 15, 2005 | Jul 15, 2005 | none ahead |
| Nobelpharmaits history only | 20 open or running | phase 1since Dec 3, 2018 | Dec 3, 2018 | none ahead |
| Vascular Therapiesits history only | 20 open or running | phase 3since Jul 29, 2015 | Jul 29, 2015 | none ahead |
| AFT Pharmaceuticalsits history only | 11 open or running | phase 2since Feb 22, 2026 | Feb 22, 2026 | Oct 2027phase 2 · NCT07436611 |
| Aucta Pharmaceuticalsits history only | 10 open or running | phase 2since Dec 1, 2017 | Dec 1, 2017 | none ahead |
| Chong Kun Dang Pharmaceuticalits history only | 11 open or running | phase 4since Jan 3, 2022 | Jan 3, 2022 | none ahead |
| Concept Medicalits history only | 11 open or running | phase 3since Jan 21, 2026 | Jan 21, 2026 | Dec 2027phase 3 · NCT07359807 |
| Dermatology Specialties Limited Partnershipits history only | 10 open or running | phase 3since Jan 29, 2019 | Jan 29, 2019 | none ahead |
| Eli Lillyits history only | 11 open or running | phase 2since May 11, 2020 | May 11, 2020 | Feb 2027phase 2 · NCT04411654 |
| Nanjing IASO Biotechnologyits history only | 11 open or running | phase 1since Dec 10, 2024 | Dec 10, 2024 | May 21, 2028phase 1 · NCT06743503 |
| TransDermits history only | 10 open or running | phase 1since Feb 5, 2014 | Feb 5, 2014 | none ahead |
- Named in CSPC Pharmaceutical Group’s own pipeline as
sirolimus for injection (albumin-bound)
, phase 4, as of Aug 20, 2026 (source).
Also a collaborator on its studies: Basilea Pharmaceutica International and MacuSight.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of CSPC Pharmaceutical Group only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 25, 2021First study: phase 1 study in Advanced Solid TumorsFirst studyNCT05125523 · 264 enrolled · China
- Aug 15, 2022Phase 1 study in Malignant Solid TumorsNCT05508620 · 270 enrolled
- Nov 14, 2022Phase 2 study in Perivascular Epithelioid Cell NeoplasmsNCT05625919 · 54 enrolled · China
- Apr 8, 2025Phase 3 study in Breast NeoplasmsNCT06929325 · 312 planned · China
- Apr 16, 2025Phase 1 study in Advanced Breast CancerNCT06941142 · 382 planned
- Apr 26, 2025Phase 2 study in Breast NeoplasmsNCT06957379 · 78 enrolled · China
- Sep 3, 2025Phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsNCT07165886 · 298 planned · China
- Jun 29, 2026Phase 2 study in Hemangioendothelioma, EpithelioidNCT07684287 · 40 planned · China
Ahead
- Oct 2027Primary completion: phase 1 study in Advanced Breast CancerNCT06941142
- Nov 30, 2027Primary completion: phase 2 study in Hemangioendothelioma, EpithelioidNCT07684287
- Aug 29, 2028Primary completion: phase 3 study in Gastroenteropancreatic Neuroendocrine TumorsNCT07165886
TargetBeta
“A natural macrocyclic lactone produced by the bacterium Streptomyces hygroscopicus, with immunosuppressant properties. In cells, sirolimus binds to the immunophilin FK Binding Protein-12 (FKBP-12) to generate an immunosuppressive complex that binds to and inhibits the activation of the mammalian …”NCIt, read by Claude
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule
Other programs on MTOR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| gedatolisibrule | Pfizer | phase 3 | 9 |
| PI3K/mTOR Kinase Inhibitor WXFL10030390rule | shanghai-jiatan-pharmatech-co-ltd | phase 3 | 6 |
| sapanisertibrule | Takeda | phase 2 | 14 |
Studies
All 8 CSPC Pharmaceutical Group leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07684287Hemangioendothelioma, Epithelioid · China | 2 | Not yet recruiting | Nov 30, 2027 | 40 |
| NCT07165886Gastroenteropancreatic Neuroendocrine Tumors · China | 3 | Recruiting | Aug 29, 2028 | 298 |
| NCT06957379Breast Neoplasms · China | 2 | Active, not recruiting | Jun 2025 | 78 |
| NCT06941142Advanced Breast Cancer | 1 | Not yet recruiting | Oct 2027 | 382 |
| NCT06929325Breast Neoplasms · China | 3 | Not yet recruiting | Oct 2026 | 312 |
| NCT05625919Perivascular Epithelioid Cell Neoplasms · China | 2 | UNKNOWN | Nov 2024 | 54 |
| NCT05508620Malignant Solid Tumors | 1 | UNKNOWN | Dec 2024 | 270 |
| NCT05125523Advanced Solid Tumors · China | 1 | UNKNOWN | Jun 2024 | 264 |
How it is read
Names in the registry
- “Sirolimus”, 28 entries
- “sirolimus”, 8 entries
- “Rapamycin”, 3 entries
- “Sirolimus for Injection (Albumin-bound)”, 3 entries
- “Rapamune® (Sirolimus)”, 3 entries
Conditions, from the studies’ own filings
- Renal Insufficiency, 7 studies
- Kidney Failure, Chronic, 3 studies
- Breast Neoplasms, 3 studies
- Tuberous Sclerosis, 2 studies
- Uveitis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.